NRAS and melanoma: Similarly, another open label, phase Ib trial focuses on the combination effect of cobimetinib and IN10018 (an adenosine triphosphate–competitive focal adhesion kinase inhibitor) in NRAS-mutant melanoma and metastatic uveal melanoma.